Cargando…
Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database
OBJECTIVES: Although several years have passed since biologic disease modifying antirheumatic drugs were introduced to the market, considerable disparities in access still remain. Tumour necrosis factor inhibitors (TNFi) have proven to be highly effective and safe for treating patients with rheumati...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423465/ https://www.ncbi.nlm.nih.gov/pubmed/37328194 http://dx.doi.org/10.1136/ard-2022-223696 |
_version_ | 1785089457797464064 |
---|---|
author | Stajszczyk, Marcin Obarska, Izabela Jeka, Slawomir Batko, Bogdan |
author_facet | Stajszczyk, Marcin Obarska, Izabela Jeka, Slawomir Batko, Bogdan |
author_sort | Stajszczyk, Marcin |
collection | PubMed |
description | OBJECTIVES: Although several years have passed since biologic disease modifying antirheumatic drugs were introduced to the market, considerable disparities in access still remain. Tumour necrosis factor inhibitors (TNFi) have proven to be highly effective and safe for treating patients with rheumatic musculoskeletal diseases (RMDs). The emergence of biosimilars is promising for cost reduction and more equitable, widespread access. METHODS: A retrospective budget impact analysis based on final drug prices was conducted using 12 687 treatment courses for infliximab, etanercept and adalimumab. Estimated and real-life savings for public payer were calculated from an 8-year perspective of TNFi use. Data on the treatment cost and on the evolution in the number of patients treated was provided. RESULTS: From a public payer perspective, the estimated total savings amount to over €243 million for TNFi, with over €166 million attributed to treatment cost reduction in RMDs. Real-life savings were calculated as €133 million and €107 million, respectively. The rheumatology sector generated between 68% and 92% of total savings across models, depending on the adopted scenario. The overall decrease in mean annual cost of treatment ranged between 75% and 89% in the study frame. If all budget savings were spent on reimbursement of additional TNFi, a hypothetical total of almost 45 000 patients with RMDs could be treated in 2021. CONCLUSIONS: This is the first nation-level analysis that shows estimated and real-life direct cost-savings for TNFi biosimilars. Transparent criteria for reinvesting savings should be developed on both a local and an international levels. |
format | Online Article Text |
id | pubmed-10423465 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-104234652023-08-14 Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database Stajszczyk, Marcin Obarska, Izabela Jeka, Slawomir Batko, Bogdan Ann Rheum Dis Treatment OBJECTIVES: Although several years have passed since biologic disease modifying antirheumatic drugs were introduced to the market, considerable disparities in access still remain. Tumour necrosis factor inhibitors (TNFi) have proven to be highly effective and safe for treating patients with rheumatic musculoskeletal diseases (RMDs). The emergence of biosimilars is promising for cost reduction and more equitable, widespread access. METHODS: A retrospective budget impact analysis based on final drug prices was conducted using 12 687 treatment courses for infliximab, etanercept and adalimumab. Estimated and real-life savings for public payer were calculated from an 8-year perspective of TNFi use. Data on the treatment cost and on the evolution in the number of patients treated was provided. RESULTS: From a public payer perspective, the estimated total savings amount to over €243 million for TNFi, with over €166 million attributed to treatment cost reduction in RMDs. Real-life savings were calculated as €133 million and €107 million, respectively. The rheumatology sector generated between 68% and 92% of total savings across models, depending on the adopted scenario. The overall decrease in mean annual cost of treatment ranged between 75% and 89% in the study frame. If all budget savings were spent on reimbursement of additional TNFi, a hypothetical total of almost 45 000 patients with RMDs could be treated in 2021. CONCLUSIONS: This is the first nation-level analysis that shows estimated and real-life direct cost-savings for TNFi biosimilars. Transparent criteria for reinvesting savings should be developed on both a local and an international levels. BMJ Publishing Group 2023-09 2023-06-16 /pmc/articles/PMC10423465/ /pubmed/37328194 http://dx.doi.org/10.1136/ard-2022-223696 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Treatment Stajszczyk, Marcin Obarska, Izabela Jeka, Slawomir Batko, Bogdan Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database |
title | Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database |
title_full | Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database |
title_fullStr | Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database |
title_full_unstemmed | Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database |
title_short | Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database |
title_sort | budget impact analysis and treatment availability with biosimilar tnf inhibitors in rheumatic diseases in poland: real-world evidence using a nationwide database |
topic | Treatment |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423465/ https://www.ncbi.nlm.nih.gov/pubmed/37328194 http://dx.doi.org/10.1136/ard-2022-223696 |
work_keys_str_mv | AT stajszczykmarcin budgetimpactanalysisandtreatmentavailabilitywithbiosimilartnfinhibitorsinrheumaticdiseasesinpolandrealworldevidenceusinganationwidedatabase AT obarskaizabela budgetimpactanalysisandtreatmentavailabilitywithbiosimilartnfinhibitorsinrheumaticdiseasesinpolandrealworldevidenceusinganationwidedatabase AT jekaslawomir budgetimpactanalysisandtreatmentavailabilitywithbiosimilartnfinhibitorsinrheumaticdiseasesinpolandrealworldevidenceusinganationwidedatabase AT batkobogdan budgetimpactanalysisandtreatmentavailabilitywithbiosimilartnfinhibitorsinrheumaticdiseasesinpolandrealworldevidenceusinganationwidedatabase |